#1
|
||||
|
||||
Òàè ðèñê îáíàðóæåíèÿ çëîêà÷åñòâ. íîâîîáðàçîâàíèÿ
Ó ëþäåé ñ íåñïðîâîöèðîâàííûì âåíîçíûì òðîìáîçîì â 2 ðàçà ïîâûøåí ðèñê îáíàðóæåíèÿ ñêðûòîãî çëîêà÷åñòâåííîãî ïðîöåññà îñîáåííî â ïåðâûå ïîëãîäà ïîñëå ðàçâèòèÿ òðîìáîçà:
Unprovoked venous thromboembolism and subsequent cancer risk: a population-based cohort study [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#2
|
|||
|
|||
Ïî ñóòè ýòî ïàðàíåîïëàñòè÷åñêèé ïðîöåññ?
|
#3
|
||||
|
||||
äà, òîëüêî çà ðóáåæîì åãî íàçûâàþò ñèíäðîìîì Òðóññî:
Trousseau's syndrome, named after the French physician Armand Trousseau who first described it in 1865, refers to recurrent or migratory spontaneous venous thrombosis, arterial embolism due to non-bacterial thrombotic endocarditis, or both, in a patient with known or occult malignancy which is usually difficult to diagnose and may even remain elusive until it is disclosed in an autopsy.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#4
|
||||
|
||||
Ïðèìåðíî òàêèå æå öèôðû ïîëó÷åíû íåñêîëüêèìè ãîäàìè ðàíåå è â Äàíèè: ðèñê âûÿâëåíèÿ îïóõîëåé â 2.5-3 ðàçà âûøå â òå÷åíèå ïåðâîãî ãîäà ïîñëå òðîìáîçîâ ðàçíîé ëîêàëèçàöèè:
Eur J Cancer. 2012 Mar;48(4):586-93. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
|||
|
|||
Âñ¸ ýòî ïîíÿòíî, à ñàìîå òî èíòåðåñíîå ýòî âîçðàñò! Åñòü êàêàÿ ëèáî êîððåëÿöèÿ?
|
#6
|
||||
|
||||
ñ âîçðàñòîì ïîâûøàåòñÿ êàê ðèñê îáíàðóæåíèÿ îïóõîëåé, òàê è ðèñê òðîìáîçîâ, óâåðåí, åñòü â ïîëíûõ òåêñòàõ è ïðî âîçðàñò ïàöèåíòîâ, íî íå â òåçèñàõ
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#7
|
|||
|
|||
Âñ¸ âåðíî, ñ âîçðàñòîì ïîâûøàåòñÿ ðèñê îáíàðóæåíèÿ îïóõîëåé, ñïîðó íåò, à ñàìîå èíòåðåñíîå ïîäîáíûé ñèíäðîì ïðîòåêàåò ó ìîëîäûõ, Âû âñòðå÷àëèñü ñ ïîäîáíûì ñèíäðîìîì â 24 ãîäà?
|
#8
|
||||
|
||||
Íàñêîëüêî çíàþ, òàêèå ñëó÷àè áûâàþò êðàéíå ðåäêî, ó ìîëîäûõ â îñíîâíîì èøóò òðîìáîôèëèþ, à íå îïóõîëü, òàê ÷åøñêèå âðà÷è îáñëåäîâàëè ëþäåé ñ òðîìáîçîì äî 50 ëåò (â ñðåäíåì 35 ëåò íà ìîìåíò òðîìáîçà) è îáíàðóæèëè îïóõîëè â 1.2% ñëó÷àåâ â òå÷åíèå ïåðâîãî ãîäà, ïîëàãàþ, ÷tî â 20-25 ëåò ðèñê îáíàðóæåíèÿ îïóõîëè ìåíåå 0.5-1% [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#9
|
|||
|
|||
Î÷åíü äàâíî, â ïåðèîä ïåðâîé ïðîãðàììû full text äîñòóïà, èíòåðåñîâàëñÿ ýòîé òåìîé.
Ïîìíèòñÿ, ÷òî Òðóññî ñâÿçûâàë ýòîò ñèìïòîì ñ ðàêîì èìåííî ïîäæåëóäî÷íîé æåëåçû è ïîçæå êàê äàæå ïîñòàâèë åãî ñåáå (íî ðàêà íå áûëî). Èç âûâîäîâ òîãî âðåìåíè - âåðîÿòíîñòü äèàãíîñòèêè ïîâûøàåòñÿ, íî íèêàêîãî áåíåôèòà îò ýòîãî íåò. Ìîæåò ÷òî è ïîìåíÿëîñü çà 18-20 ëåò? |
#10
|
||||
|
||||
èç íàèáîëåå çíà÷èìûõ â ïîñëåäíåå âðåìÿ ïóáëèêàöèé íà åòó òåìó áûëà íåäàâíÿÿ â ÍÅÉÌå èç Êàíàäû - â ïîëíîì òåêñòå ïëþñ ðåä. êîììåíòàðèé è ïåðåïèñêà:
Screening for Occult Cancer in Unprovoked Venous Thromboembolism [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |